14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CLYM vs NBP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over NBP (NBP) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLYM carries a Unified Composite Score of 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While NBP currently prints a higher short-term Unified Composite Score (51.9/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs NBP. Trailing 12-month operating profitability (CLYM 0.0% vs NBP 0.0%) and valuation multiples (CLYM N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $96.3M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CLYM vs NBP Key Questions & Quantitative Answers
As of Nov 16, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over NBP (NBP) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLYM carries a Unified Composite Score of 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NBP currently prints a higher short-term Unified Composite Score (51.9/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLYM leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus N/A for NBP. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NBP.
NBP screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus NBP (-59.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk). By comparison, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 81% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.